Immuron Limited (ASX:IMC)
0.0330
+0.0030 (10.00%)
At close: Mar 26, 2026
Immuron Revenue
In the fiscal year ending June 30, 2025, Immuron had annual revenue of 7.29M AUD with 48.63% growth. Immuron had revenue of 2.55M in the half year ending June 30, 2024, with 376.82% growth.
Revenue
7.29M
Revenue Growth
+48.63%
P/S Ratio
1.44
Revenue / Employee
1.07M
Employees
7
Market Cap
10.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.37M | -94.21% |
| Jun 30, 2020 | 2.52M | 131.14K | 5.49% |
| Jun 30, 2019 | 2.39M | 544.52K | 29.55% |
| Jun 30, 2018 | 1.84M | 446.71K | 31.99% |
| Jun 30, 2017 | 1.40M | 395.12K | 39.47% |
| Jun 30, 2016 | 1.00M | -1.30K | -0.13% |
| Jun 30, 2015 | 1.00M | 21.33K | 2.17% |
| Jun 30, 2014 | 981.05K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 9.75M |
| Noxopharm | 3.40M |
| Tissue Repair | 3.38M |
| Nexalis Therapeutics | 761.96K |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |
| Invex Therapeutics | 229.08K |
| Patrys | 100.38K |
Immuron News
- 22 days ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 22 days ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 2 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 2 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire
- 4 months ago - Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes - GuruFocus
- 5 months ago - Immuron (IMRN) Secures FDA Approval for Phase 2 Trial of IMM-529 - GuruFocus
- 5 months ago - Immuron: FDA Approves IND Application For IMM-529 - Nasdaq
- 5 months ago - Immuron IMM-529 IND approved by FDA - GlobeNewsWire